Medtronic plc [MDT] Revenue clocked in at $30.81 billion, down -24.95% YTD: What’s Next?

Medtronic plc [NYSE: MDT] jumped around 0.14 points on Tuesday, while shares priced at $77.64 at the close of the session, up 0.18%. The company report on December 20, 2022 that New Leadership Reinforces Medtronic Foundation’s Commitment To ID&E.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

The Medtronic Foundation is headed into a new era with the appointment of Dr. Sally Saba as President. The Chief Inclusion & Diversity Officer at Medtronic has overseen inclusion, diversity, and equity (ID&E) at Medtronic since 2020.

Having a leader who can drive the strategic work of both the Medtronic Foundation and inclusion, diversity, and equity (ID&E) at Medtronic and will help us take on the toughest equity challenges and take our employee engagement in community to the next level.

Medtronic plc stock is now -24.95% down from its year-to-date (YTD) trading value. MDT Stock saw the intraday high of $77.90 and lowest of $76.50 per share. The company’s 52-week high price is 114.31, which means current price is +2.47% above from all time high which was touched on 04/21/22.

Compared to the average trading volume of 7.16M shares, MDT reached a trading volume of 5335810 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Medtronic plc [MDT]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MDT shares is $93.89 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MDT stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Oppenheimer have made an estimate for Medtronic plc shares, keeping their opinion on the stock as Perform, with their previous recommendation back on November 23, 2022. While these analysts kept the previous recommendation, Citigroup raised their target price from $108 to $85. The new note on the price target was released on November 23, 2022, representing the official price target for Medtronic plc stock. Previously, the target price had yet another raise to $85, while Deutsche Bank analysts kept a Hold rating on MDT stock.

The Average True Range (ATR) for Medtronic plc is set at 1.70, with the Price to Sales ratio for MDT stock in the period of the last 12 months amounting to 3.34. The Price to Book ratio for the last quarter was 1.99, with the Price to Cash per share for the same quarter was set at 8.63. Price to Free Cash Flow for MDT in the course of the last twelve months was 77.58 with Quick ratio for the last quarter at 1.40.

How has MDT stock performed recently?

Medtronic plc [MDT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.67. With this latest performance, MDT shares dropped by -1.87% in over the last four-week period, additionally sinking by -12.96% over the last 6 months – not to mention a drop of -25.65% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MDT stock in for the last two-week period is set at 44.92, with the RSI for the last a single of trading hit 46.48, and the three-weeks RSI is set at 44.43 for Medtronic plc [MDT]. The present Moving Average for the last 50 days of trading for this stock 80.92, while it was recorded at 77.23 for the last single week of trading, and 92.14 for the last 200 days.

Medtronic plc [MDT]: Deeper insight into the fundamentals

Medtronic plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.80.

Earnings analysis for Medtronic plc [MDT]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MDT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Medtronic plc go to 2.94%.

Insider trade positions for Medtronic plc [MDT]

There are presently around $84,647 million, or 84.60% of MDT stock, in the hands of institutional investors. The top three institutional holders of MDT stocks are: VANGUARD GROUP INC with ownership of 123,861,994, which is approximately 0.861% of the company’s market cap and around 0.09% of the total institutional ownership; BLACKROCK INC., holding 115,998,561 shares of the stock with an approximate value of $9.01 billion in MDT stocks shares; and STATE STREET CORP, currently with $4.58 billion in MDT stock with ownership of nearly 1.6% of the company’s market capitalization.

Positions in Medtronic plc stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 1,000 institutional holders increased their position in Medtronic plc [NYSE:MDT] by around 63,377,828 shares. Additionally, 889 investors decreased positions by around 46,644,505 shares, while 223 investors held positions by with 980,230,734 shares. The mentioned changes placed institutional holdings at 1,090,253,067 shares, according to the latest SEC report filing. MDT stock had 87 new institutional investments in for a total of 6,574,485 shares, while 154 institutional investors sold positions of 6,180,231 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here